AllerFund
Overview
AllerFund is a venture capital firm focused on investing in early-stage companies that develop treatments, diagnostics, and products for individuals with food allergies. The firm collaborates with scientists and entrepreneurs to build businesses around promising research and technologies, providing critical business advice and support. The firm's investment strategy emphasizes the clinical and community impact of its portfolio companies, aiming to create therapeutic, diagnostic, or tool-based solutions that significantly improve the lives of those with food allergies. AllerFund's portfolio includes investments in therapeutics, medical devices, diagnostics, digital technologies, and consumer products. AllerFund's team comprises experienced professionals specializing in growth-stage investments across technology and healthcare sectors. The firm is known for its data-driven approach and emphasizes strategic partnerships to enhance portfolio value, supporting sustainable scaling and innovation within its investee companies.
Investment Focus
- Early-stage companies developing solutions for food allergies
Portfolio Companies
Reach AllerFund directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about AllerFund
What sectors does AllerFund invest in?
AllerFund invests in Health Care, Biotechnology, Medical, Health Diagnostics and Personal Health, and is based in New York, United States. AllerFund is listed as a venture capital in the ConnectSafely investor database.
What stage does AllerFund invest at?
AllerFund backs companies at Seed and Series A, writing cheques of 100K - 1M.
Which regions does AllerFund invest in?
AllerFund invests across United States and Germany.
What companies has AllerFund invested in?
AllerFund's portfolio includes ATANIS Biotech AG.
Last updated · Source: ConnectSafely investor database
